Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) shot up 4.8% during mid-day trading on Friday. The stock traded as high as $19.15 and last traded at $19.4040. 113,136 shares were traded during trading, a decline of 89% from the average session volume of 1,019,825 shares. The stock had previously closed at $18.52.
Wall Street Analyst Weigh In
Several brokerages have commented on VOR. Wall Street Zen cut shares of Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Stifel Nicolaus set a $40.00 price target on Vor Biopharma in a research note on Monday, November 2nd. William Blair initiated coverage on Vor Biopharma in a report on Wednesday, October 21st. They set an “outperform” rating on the stock. Weiss Ratings raised shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Finally, Wedbush raised their target price on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $38.29.
View Our Latest Analysis on VOR
Vor Biopharma Stock Up 3.6%
Vor Biopharma (NASDAQ:VOR – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.64). On average, sell-side analysts predict that Vor Biopharma Inc. will post -2.74 earnings per share for the current year.
Hedge Funds Weigh In On Vor Biopharma
A number of large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its position in Vor Biopharma by 28,408.1% in the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after purchasing an additional 112,496 shares during the last quarter. Braidwell LP increased its position in Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after purchasing an additional 106,330 shares during the period. Renaissance Technologies LLC bought a new position in shares of Vor Biopharma in the 1st quarter valued at about $2,298,000. Wellington Management Group LLP acquired a new stake in shares of Vor Biopharma during the 2nd quarter worth approximately $499,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Vor Biopharma during the 2nd quarter worth approximately $1,799,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.
Vor Biopharma Company Profile
Vor Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33.
Featured Articles
- Five stocks we like better than Vor Biopharma
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
